Coherus Oncology financials
$1.18+3.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3M | $12.3M | $12.7M | $11.6M | $10.3M | $7.6M | $7.7M | $6.1M | $10.3M | $2.3M | $91.5M | $74.6M |
| Gross profit | $10.1M | $8.5M | $8.7M | $7.8M | $6.9M | $4.9M | $5.0M | $3.3M | $8.5M | $869.0K | $7.0M | $41.9M |
| Gross margin | 70.4% | 69.0% | 68.3% | 67.8% | 66.9% | 65.1% | 64.4% | 54.9% | 82.4% | 37.7% | 7.6% | 56.1% |
| Operating income | -$32.3M | -$36.2M | -$45.9M | -$44.3M | -$45.5M | -$45.4M | -$45.4M | -$46.9M | -$39.6M | -$67.8M | -$68.9M | -$32.0M |
| Net income | -$20.6M | -$38.3M | -$37.6M | -$35.5M | $297.8M | -$56.6M | -$50.7M | -$10.8M | -$12.9M | $102.9M | -$79.7M | -$39.6M |
| Net margin | −144.2% | −311.3% | −295.3% | −307.1% | 2903.9% | −744.4% | −655.6% | −177.6% | −125.5% | 4457.3% | −87.0% | −53.2% |
| Diluted EPS | $-0.13 | $-0.28 | $-0.31 | $-0.31 | $2.57 | $-0.49 | $-0.44 | $-0.09 | $-0.11 | $0.91 | $-0.71 | $-0.41 |
| EBITDA | -$31.5M | -$35.3M | -$45.0M | -$43.4M | -$44.5M | -$44.4M | -$44.4M | -$45.3M | -$38.4M | -$66.3M | -$67.8M | -$31.1M |
| Operating cash flow | -$62.1M | -$57.9M | -$19.7M | -$46.3M | -$46.6M | -$25.8M | $28.6M | -$62.0M | $59.7M | -$46.8M | -$12.9M | -$54.3M |
| Free cash flow | -$62.1M | -$57.9M | -$498.4M | -$46.3M | -$51.4M | -$30.5M | -$199.2M | -$62.0M | $19.7M | -$234.6M | -$12.9M | -$54.3M |
| Diluted shares | 154.8M | 136.4M | 120.4M | 116.2M | 116.1M | 115.9M | 115.4M | 115.2M | 114.8M | 112.7M | 112.4M | 97.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $82.9M | $115.2M | $88.9M | $103.4M | $216.9M | $82.4M |
| Short-term investments | $22.4M | $51.8M | $83.2M | $88.3M | $20.7M | $0.00 |
| Total debt | $37.2M | $37.1M | $37.1M | $0.00 | $0.00 | $265.4M |
| Total assets | $191.2M | $266.0M | $258.3M | $516.5M | $439.5M | $371.1M |
| Total liabilities | $130.3M | $187.4M | $197.3M | $428.7M | $319.6M | $554.5M |
| Shareholders' equity | $60.8M | $78.6M | $61.0M | $87.8M | $119.8M | -$183.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology